Switch theme
Sign up to access all valuation multiples
Autobio Diagnostics Co Ltd is a clinical diagnostics company in China. It specializes in research and development, production and sales of in vitro diagnostic reagents and instruments.
1999
n/a
LTM Revenue $630M
LTM EBITDA $248M
$3.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Autobio Diagnostics has a last 12-month revenue (LTM) of $630M and a last 12-month EBITDA of $248M.
In the most recent fiscal year, Autobio Diagnostics achieved revenue of $621M and an EBITDA of $248M.
Autobio Diagnostics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Autobio Diagnostics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $630M | XXX | $621M | XXX | XXX | XXX |
| Gross Profit | $409M | XXX | $406M | XXX | XXX | XXX |
| Gross Margin | 65% | XXX | 65% | XXX | XXX | XXX |
| EBITDA | $248M | XXX | $248M | XXX | XXX | XXX |
| EBITDA Margin | 39% | XXX | 40% | XXX | XXX | XXX |
| EBIT | $177M | XXX | $176M | XXX | XXX | XXX |
| EBIT Margin | 28% | XXX | 28% | XXX | XXX | XXX |
| Net Profit | $169M | XXX | $166M | XXX | XXX | XXX |
| Net Margin | 27% | XXX | 27% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Autobio Diagnostics's stock price is CNY 39 (or $5).
Autobio Diagnostics has current market cap of CNY 22.3B (or $3.1B), and EV of CNY 22.2B (or $3.1B).
See Autobio Diagnostics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.1B | $3.1B | XXX | XXX | XXX | XXX | $0.30 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Autobio Diagnostics has market cap of $3.1B and EV of $3.1B.
Autobio Diagnostics's trades at 5.0x EV/Revenue multiple, and 12.4x EV/EBITDA.
Equity research analysts estimate Autobio Diagnostics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Autobio Diagnostics has a P/E ratio of 18.3x.
See valuation multiples for Autobio Diagnostics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.1B | XXX | $3.1B | XXX | XXX | XXX |
| EV (current) | $3.1B | XXX | $3.1B | XXX | XXX | XXX |
| EV/Revenue | 4.9x | XXX | 5.0x | XXX | XXX | XXX |
| EV/EBITDA | 12.4x | XXX | 12.4x | XXX | XXX | XXX |
| EV/EBIT | 17.4x | XXX | 17.5x | XXX | XXX | XXX |
| EV/Gross Profit | 7.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 18.3x | XXX | 18.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 34.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAutobio Diagnostics's last 12 month revenue growth is 7%
Autobio Diagnostics's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Autobio Diagnostics's rule of 40 is 49% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Autobio Diagnostics's rule of X is 58% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Autobio Diagnostics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 39% | XXX | 40% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | 1% | XXX | XXX | XXX |
| Rule of 40 | 49% | XXX | 47% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 58% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 16% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 37% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Autobio Diagnostics acquired XXX companies to date.
Last acquisition by Autobio Diagnostics was XXXXXXXX, XXXXX XXXXX XXXXXX . Autobio Diagnostics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Autobio Diagnostics founded? | Autobio Diagnostics was founded in 1999. |
| Where is Autobio Diagnostics headquartered? | Autobio Diagnostics is headquartered in China. |
| Is Autobio Diagnostics publicy listed? | Yes, Autobio Diagnostics is a public company listed on SHG. |
| What is the stock symbol of Autobio Diagnostics? | Autobio Diagnostics trades under 603658 ticker. |
| When did Autobio Diagnostics go public? | Autobio Diagnostics went public in 2016. |
| Who are competitors of Autobio Diagnostics? | Similar companies to Autobio Diagnostics include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Autobio Diagnostics? | Autobio Diagnostics's current market cap is $3.1B |
| What is the current revenue of Autobio Diagnostics? | Autobio Diagnostics's last 12 months revenue is $630M. |
| What is the current revenue growth of Autobio Diagnostics? | Autobio Diagnostics revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Autobio Diagnostics? | Current revenue multiple of Autobio Diagnostics is 4.9x. |
| Is Autobio Diagnostics profitable? | Yes, Autobio Diagnostics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Autobio Diagnostics? | Autobio Diagnostics's last 12 months EBITDA is $248M. |
| What is Autobio Diagnostics's EBITDA margin? | Autobio Diagnostics's last 12 months EBITDA margin is 39%. |
| What is the current EV/EBITDA multiple of Autobio Diagnostics? | Current EBITDA multiple of Autobio Diagnostics is 12.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
